key: cord-0698982-u25usodk
authors: Mann, Douglas L.; Greene, Stephen J.; Givertz, Michael M.; Vader, Justin M.; Starling, Randall C.; Ambrosy, Andrew P.; Shah, Palak; McNulty, Steven E.; Mahr, Claudius; Gupta, Divya; Redfield, Margaret M.; Lala, Anuradha; Lewis, Gregory D.; Mohammed, Selma F.; Gilotra, Nisha A.; DeVore, Adam D.; Gorodeski, Eiran Z.; Desvigne-Nickens, Patrice; Hernandez, Adrian F.; Braunwald, Eugene
title: Sacubitril/Valsartan in Advanced Heart Failure with Reduced Ejection Fraction: Rationale/Design of the LIFE Trial
date: 2020-06-10
journal: JACC Heart Fail
DOI: 10.1016/j.jchf.2020.05.005
sha: e9d8b303bada3c9d1187578269a34499aab2239a
doc_id: 698982
cord_uid: u25usodk

Abstract The PARADIGM-HF trial reported that sacubitril/valsartan (S/V), an angiotensin receptor-neprilysin inhibitor, significantly reduced mortality and heart failure (HF) hospitalization in HF patients with a reduced ejection fraction (HFrEF). However, fewer than 1% of patients in PARADIGM-HF had NYHA class IV symptomology; accordingly, data that informs the use of S/V among patients with advanced HF are limited. The LIFE (LCZ696 In Hospitalized Advanced Heart FailurE) study is a 24-week prospective, multicenter, double-blinded, double-dummy, active-comparator trial to assess the safety, efficacy and tolerability of S/V compared with V in patients with advanced HFrEF. The trial planned to randomize 400 patients age ≥18 years with advanced HF, defined as an EF ≤35%, NYHA functional class IV symptoms, elevated natriuretic peptide concentration (B-type natriuretic peptide [BNP] ≥250 pg/mL or N-terminal-pro-B-type natriuretic peptide [NT-proBNP] ≥800 pg/mL), and ≥1 objective finding(s) of advanced HF. Following a 3-7 day open-label run-in period with S/V 24/26 mg twice daily, patients are randomized 1:1 to S/V titrated to 97/103 mg twice daily versus 160 mg V twice daily. The primary endpoint is the proportional change from baseline in the area under the curve for NT-proBNP levels measured through week 24. Secondary and tertiary endpoints include clinical outcomes, as well as safety and tolerability. Because of the COVID-19 pandemic enrollment in the LIFE trial was stopped prematurely to ensure patient safety and data integrity. The primary analysis will consist of the first 335 randomized patients, whose clinical follow-up was not severely impacted by COVID-19.

The use of evidence-based medical therapies has been shown to improve survival, heart failure (HF) hospitalizations and quality of life for patients with HF and reduced ejection fraction (HFrEF) who have mild to moderate symptoms (1, 2) . However, the evidence base for the use of medical therapy among patients with HFrEF and advanced symptoms is less comprehensive, insofar as it is often difficult to achieve the dose(s) of neurohormonal antagonist recommended in clinical trials in these patients, because of dose-limiting symptomatic hypotension, worsening renal function or both (3) . Consequently, contemporary guidelines for patients with advanced HFrEF do not focus on medical therapy, and instead recommend that these patients should be considered for mechanical circulatory support, cardiac transplantation, or palliative care (1, 4) .

Blocker Neprilysin Inhibitor With Angiotensin-Converting Enzyme Inhibitor to Determine Impact on Global Mortality and Morbidity in Heart Failure) randomized trial compared sacubitril/valsartan (S/V) with enalapril in ambulatory patients with HFrEF. S/V reduced the rates of cardiovascular (CV) mortality or hospitalization for HF by a relative 20%, and all-cause mortality by a relative 16% (5, 6) . Based on actuarial estimates of event rates and life expectancy, S/V is expected to prolong survival by about 1-2 years in ambulatory HFrEF patients, across a wide range of age groups (7) . The 5-year estimated number needed to treat was 14, when S/V was compared to enalapril, for the primary outcome of CV death or HF hospitalization (8) . As a result of these findings, the U.S. Food and Drug Administration (FDA) approved S/V for treatment of HFrEF, and the American College of Cardiology/American Heart Association/Heart Failure Society of America updated their guidelines to recommend (Class I) the use of S/V to further reduce morbidity and mortality in HFrEF (9, 10) .

Association (NYHA) functional class II-IV symptoms, <1% of patients in PARADIGM-HF had NYHA class IV symptoms at the time of enrollment. In order to be randomized into the PARADIGM-HF trial, patients had to be receiving and tolerating a stable dose of a beta-blocker and an angiotensin converting enzyme inhibitor (ACEi) that was equivalent to ≥10 mg of enalapril daily for 4 weeks, as well as have a screening systolic blood pressure ≥100 mmHg.

Moreover, nearly 20% of patients that were screened for PARADIGM-HF were unable to complete the two run-in periods, which required that patients tolerate a maximal dose of 10 mg twice daily of enalapril for 2 weeks followed by a 4-6 week treatment with S/V up to 97/103 mg twice daily. Variables that were associated with non-completion of the run-ins included a lower blood pressure and lower glomerular filtration rate: both hallmarks of patients with advanced HF (11, 12) . The recent PIONEER-HF trial, which tested S/V in a higher risk population of patients hospitalized for acute HFrEF only included 9% of patients with NYHA class IV symptoms (13) .

In light of this evidence gap among chronic HFrEF patients with severe symptoms, current guidelines do not provide guidance with regard to the use of S/V for HFrEF patients with advanced HF (9) (10). Here we report on the design of the LIFE (LCZ696 in Advanced Heart Failure) clinical trial, which will test the hypothesis that treatment with S/V will improve levels of NT-proBNP and clinical status when compared to treatment with V alone, in HFrEF patients with NYHA class IV symptoms (clinical trials.gov identifier NCT02816736).

The LIFE (LCZ696 In Hospitalized Advanced Heart FailurE) trial is a 24-week prospective, multicenter, double-blinded, double-dummy, active-comparator trial to assess the safety, efficacy and tolerability of S/V compared with V in patients with advanced HFrEF. The key inclusion and exclusion criteria are shown in Table 1 October 2018 , systolic blood pressure <90 mmHg, estimated glomerular filtration rate (eGFR) <20 mL/min/1.73 m 2 , and serum potassium >5.5 mmol/L.

The study is composed of 3 phases: 1) screening visit; 2) open-label run-in period; and 3) double-blind treatment phase (Table 2 ; Central Illustration). At the screening visit, a complete history, physical examination, and laboratory evaluation are performed to assess eligibility. In subjects taking an ACEi at baseline, the ACEi is held for >36 hours before beginning the run-in period with open-label S/V (2) . Patients meeting all eligibility criteria are enrolled and begin an unblinded run-in period of 3-7 days with S/V 24/26 mg per os (p.o) twice daily (BID). Of note, the screening visit, enrollment, and the run-in period can be begun on the same day for outpatients who are not taking an ACEi and for whom laboratory results have been reviewed and eligibility confirmed. The run-in period must begin within 7 days of the screening visit. • For patients who are ACEi/ARB naïve, previously taking a low-dose of an ACEi/ARB (e.g., Dose adjustments of study drug may be performed every 2 weeks by doubling the dose of study medication up to the target or maximally tolerated sub-target dose. Criteria for doubling the dose are based on a systolic blood pressure ≥90 mmHg, the absence of symptomatic hypotension, and the absence of worsening renal function or a serum creatinine >2 mg/dL. For patients not tolerating the dose of study medication administered, the dose is reduced to the dose previously tolerated. At the conclusion of the 24-week double-blind treatment phase, transition to open-label S/V or V is at the discretion of the treating physician. The study participants and study team remain blinded until after the completion of the trial and the database has been locked and made available.

The primary endpoint is the proportional change in the area under the curve for NT-proBNP levels measured at baseline and at weeks 2, 4, 8, 12, and 24. The secondary efficacy endpoint assessed over a 24 week period includes the number of days where the patient is alive, out of hospital, and free from any of the following events: listing for cardiac transplantation (Status 1-4), cardiac transplantation, LVAD implantation or placed on continuous inotropic therapy for ≥ 7 days, hospitalization for HF on > 2 occasions (other than the index admission).

Secondary tolerability endpoints include an analysis through 24 weeks of the number of subjects who (1) achieved a target dose of 25%, 50% or 100% of V or S/V, (2) developed hypotension (SBP ≤ 85 mmHg) with symptoms, (3) developed worsening renal function (eGFR <20 ml/min/1.73m²), or (4) developed moderate (> 5.5 mmol/L) or severe (≥ 6 mmol/L) hyperkalemia. Tertiary endpoints include a time to event analysis through 24 weeks for death, first hospitalization for HF, first hospitalization for HF or death. Additional tertiary endpoints comparing S/V with V over 24 week period include: the total number of HF hospitalizations, as well as the number of patients who required chronic inotropic support > 7 days after discharge from the index hospitalization, were listed for heart transplantation (i.e. status 1-4), underwent heart transplantation, or were implanted with an LVAD, had a change in baseline levels eGFR and cystatin C, measured at 4, 8, 12, and 24 weeks, had unanticipated use of intravenous diuretics (outpatient, emergency room, or inpatient); had a change in the AUC in patient-reported quality of life as measured by the Kansas City Cardiomyopathy Questionnaire. In addition, there is a pre-specified exploratory hierarchical endpoint with 4 levels including 1) death, 2) LVAD or Heart Transplant (including listing status of 1A, 1B or 1-4), 3) multiple HF hospital admissions, and 4) single HF admission. There will also be an exploratory endpoint of CV death or HF hospitalization.

The final analytical cohort will include all randomized patients. Descriptive statistics will be provided for demographics and baseline clinical characteristics. All continuous data will be reported as a mean ± standard deviation or median IQI (25 th , 75 th ). Categorical data will be reported as frequencies and percentages. Baseline differences between treatment groups will be assessed using chi-square or Fisher's exact test for categorical variables and the Wilcoxon twosample test for continuous variables.

Analyses of all study endpoints will be based on intention-to-treat. The primary hypothesis is that the area under the curve (AUC) for NT-proBNP levels measured at weeks 2, 4, 8, 12, and 24 will be smaller among patients randomized to S/V, as compared with V. A general linear model will be used to estimate and compare the log-transformed AUCs in NT-proBNP values between the two treatment groups. The analysis of NT-proBNP values used for the primary analysis will be determined in a Biomarker Core Laboratory (Burlington, VT). Each patient will have one response based on the log of the proportional change from baseline in the AUC from the 2, 4, 8, 12, and 24 week measurements. The treatment effect will be summarized using a point estimate and 95% confidence interval. Based on a 2-sample t-test with type I error of 0.05 two-sided, the total sample size of 400 randomized subjects will provide 80% and 90% power to detect differences of 19% and 21% respectively for S/V compared to V. If there are missing NT pro-BNP values at week 24, the last observation from previous post-baseline time point with available NT pro-BNP data will be carried forward with available NT Pro BNP data.

For the primary analysis, no adjustment will be made for missing baseline results.

The secondary and tertiary endpoints will be analyzed using models that contain an indicator variable for the treatment assignment and atrial fibrillation status at enrollment. Continuous endpoints will be modeled using general linear regression while categorical endpoints will be modeled using logistic regression. Cox regression modeling will be used for the time-to-event analyses to estimate hazard ratios between the treatments. Kaplan-Meier curves will be generated to graphically display the event rates as a function of time from randomization in each treatment arm. Mixed models will be used for the analysis of longitudinal data. The unmatched Win Ratio estimator will be used to analyze the exploratory four-level hierarchical endpoint (14) .

The LIFE trial is funded primarily by the National Heart, Lung, and Blood Institute (NHLBI) as part of the Heart Failure Clinical Research Network. Novartis is supplying study drug, as well as supplemental funding for coordinating center operations to support trial completion. The Duke Clinical Research Institute Durham, NC is the coordinating center.

Overall responsibility for the oversight and management of the trial lies with the LIFE Steering Committee, which is comprised of academic investigators and representatives from the NHLBI.

The data and safety monitoring board (DSMB) includes HF specialists and independent statistician, and is responsible for active surveillance of safety data, including all adverse events.

The LIFE trial protocol was approved by the Institutional Review Board (IRB) at all of the participating recruiting centers.

The guideline-directed medical therapies (GDMT) recommended for all patients with chronic NYHA class IV HF include β-blockers, renin-angiotensin system inhibitors (ACEi/ARB) and mineralocorticoid receptor antagonists; whereas isosorbide dinitrate/hydralazine is also indicated as an adjunct to standard therapy in self-identified black patients with NYHA class III-IV symptoms. Although S/V is FDA approved for use in NYHA class II-IV HFrEF, current guidelines do not provide guidance regarding the use of S/V in class IV HFrEF patients because of the limited evidence base to inform use in this group of patients (9) . The LIFE trial is designed to fill the knowledge gap with respect to the safety, efficacy and tolerability of S/V in HFrEF patients with chronic NYHA class IV symptoms, and will provide important information regarding the use of S/V in the management of patients with advanced HF. Apart from the specific characteristics of the target population in the LIFE trial, several other features of the trial warrant discussion: 1) In comparison with PARADIGM-HF, in which there were two sequential run-in phases that required all patients to tolerate high-dose enalapril (10 mg BID) for 2 weeks followed by 4-6 weeks of maximal dose S/V (97/103 mg BID), the run-in period in the LIFE trial is only 3-7 days and requires that the patient only tolerate low dose S/V (24/26 mg BID) (6);

2) The comparator arm of LIFE is valsartan as opposed to enalapril, which was used in the PARADIGM-HF study. Although valsartan was used as the active comparator in trials of patients with HF with preserved ejection fraction (15, 16) , the LIFE trial will be the first trial to provide a direct comparison of the incremental effect of the neprilysin inhibitor sacubitril in patients with HFrEF;

3) The LIFE trial does not exclude patients on intravenous inotropic agents, and will therefore provide information on the use of S/V in this challenging patient population. In addition, patients may be enrolled with low systolic blood pressure (90-100 mmHg) and eGFR (20-30 mL/min/1.73).

HFrEF trials have usually been separated into studying either hospitalized patients or outpatients, LIFE is one of the first multi-center HF trials that includes patients in both categories (17, 18) . Patients meeting objective criteria consistent with advanced HF and other selection criteria are eligible regardless of inpatient or outpatient status. With increasing recognition that decision-making regarding hospital admission and discharge is subject to a variety of non-clinical factors independent of HF severity (e.g., local healthcare infrastructure, geographic region or country, medico-legal liability and reimbursement factors), the results of LIFE may apply broadly to patients with advanced HF who are cared for in a wide variety of health systems (17, 18) .

Several limitations of the LIFE trial should be noted. First, the classification and eligibility criteria for advanced HF (e.g., EF, cardiopulmonary exercise testing, and 6-minute walk testing) are determined on the basis of local testing and local clinical judgment, and may therefore be subject to some variability across study sites. Likewise, institutional and clinician practice patterns for use of inotropic agents may also vary across sites. Nonetheless, these differences are consistent with the realities of routine care delivery in the U.S., which may enhance the application of trial results to real-world clinical care. Finally, although mortality and hospitalization data are collected during study follow-up, LIFE is underpowered to detect statistically significant differences in these endpoints and findings for these study outcomes should be viewed as exploratory.

Data regarding effectiveness of medical therapy for patients with advanced HFrEF are limited (see Table 4 ), and survival without heart transplantation or LVAD therapy is exceedingly poor (3) . Although the use of S/V has been shown to have clinical benefits among HFrEF patients with mild to moderate symptoms, the evidence with respect to the safety, efficacy and tolerability for use of S/V in patients with advanced HF is limited, and it is unclear whether the clinical benefits of S/V will be of similar or different magnitude in patients with more advanced HFrEF. The LIFE trial is designed to address a critical knowledge gap regarding the use of S/V in severely symptomatic HFrEF patients, and will provide important new information that will inform the use of S/V as a treatment option for patients with advanced HF.

Because of the high-risk for adverse outcomes related to COVID-19 infection in heart failure patients, the Executive Committee of the Heart Failure Network suspended enrollment into the LIFE trial on March 23, 2020. Subsequent to this suspension, the Executive Committee considered that patients enrolled in the LIFE trial would have great difficulty attending study visits on their planned schedule secondary to restrictions placed on outpatient visits at many institutions, which meant that patients would be unable to participate in study-related procedures such as biomarker sample collection, which comprises the primary endpoint for this trial.

Additionally, due to restrictions on clinic access and potential concerns with patients going to the emergency department where exposure risk to COVID-19 is increased, the Executive Committee anticipated that the reporting of clinical endpoints such as emergency department visits and even hospit al admissions would be impacted significantly by the pandemic. Therefore, due to the unexpected disruption brought on by the COVID-19 pandemic, the LIFE protocol was amended to restrict the reported analyses to those patients that had their Week 12 visit prior to March 1, 2020, when the COVID-19 pandemic became more active in the continental United States. The data analysis plan of the LIFE trial was changed so that the primary analyses includes only those patients who were randomized on December 7, 2019 or earlier (n = 335). Additionally, any study visits performed after March 1, 2020 are excluded from the primary analyses if the patients were randomized on or prior to December 7, 2019. Patients enrolled after December 7, 2019 (n= 30) will contribute to secondary analyses of the trial, so that all randomized patients contribute to the results of the LIFE trial. Based on a 2-sample t-test with type I error of 0.05 two-sided, a revised conditional power analysis indicates that a total sample size of 335 randomized subjects will provide 72% and 84% power to detect differences of 19% and 21% respectively for S/V compared to V, respectively. The NHLBI concurred with the decision to suspend enrollment and the above changes to the LIFE trial were communicated to the NHLBI and to the DSMB on April 13, 2020 . A timeline of the LIFE trial that includes the original planned timeline for the trial, as well as how COVID-19 changed the timeline is summarized in Figure 1 . Figure 1 : Timeline for LIFE trial. LIFE trial time lines are shown from the first patient enrolled, and the data of the first DSMB interim analysis. Enrollment in the trial was suspended March 23rd, 2020 because of the high risk for adverse outcomes related to COVID-19. The data analysis plan was adjusted to restrict the primary analysis to patients who had their week 12 visit prior to March 1, 2020. The last anticipated 24 week follow-up visit for patients randomized before March 23 rd is anticipated to be October 24, 2020.

Central Illustration: Overview of Study Protocol and Timeline. The screening visit (Visit 0) and Visit 1 may be combined at the investigator's discretion for subjects who are stable and for whom lab results have been reviewed as long as the investigator ensures the 1st dose of sacubitril/valsartan > 36 hours after last ACEI dose (if applicable). If not combined, Visit 1 should take place within 7 days of the Screening Visit. Abbreviations: BID, twice daily; S/V, sacubitril/valsartan; w, week 

ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines

ACC/AHA/HFSA Focused Update on New Pharmacological Therapy for Heart Failure: An Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of

Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America

Outcomes with ambulatory advanced heart failure from the Medical Arm of Mechanically Assisted Circulatory Support (MedaMACS) Registry

Advanced (stage D) heart failure: a statement from the Heart Failure Society of America Guidelines Committee

Dual angiotensin receptor and neprilysin inhibition as an alternative to angiotensin-converting enzyme inhibition in patients with chronic systolic heart failure: rationale for and design of the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM-HF)

Angiotensin-neprilysin inhibition versus enalapril in heart failure

Estimating the Long-Term Treatment Benefits of Sacubitril-Valsartan

Estimated 5-Year Number Needed to Treat to Prevent Cardiovascular Death or Heart Failure Hospitalization With Angiotensin Receptor-Neprilysin Inhibition vs Standard Therapy for Patients With Heart Failure With Reduced Ejection Fraction: An Analysis of Data From the PARADIGM-HF Trial

ACC/AHA/HFSA Focused Update of the

Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America

ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC

Factors Associated With Noncompletion During the Run-In Period Before Randomization and Influence on the Estimated Benefit of LCZ696 in the PARADIGM-HF Trial

Baseline characteristics and treatment of patients in prospective comparison of ARNI with ACEI to determine impact on global mortality and morbidity in heart failure trial (PARADIGM-HF)

Acute Decompensated Heart Failure

The win ratio: a new approach to the analysis of composite endpoints in clinical trials based on clinical priorities

The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial

Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction

Outpatient Worsening Heart Failure as a Target for Therapy: A Review

Outpatient versus inpatient worsening heart failure: distinguishing biology and risk from location of care

Effects of enalapril on mortality in severe congestive heart failure: results of the cooperative north scandanavian enalapril survival study

Effect of carvedilol on survival in severe chronic heart failure

Safety and efficacy of carvedilol in severe heart failure. The U.S. Carvedilol Heart Failure Study Group

The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators

Combination of isosorbide dinitrate and hydralazine in blacks with heart failure

Effect of amlodipine on morbidity and mortality in severe chronic heart failure

Effect of amlodipine on the survival of patients with severe chronic heart failure due to a nonischemic cardiomyopathy: results of the PRAISE-2 study (prospective randomized amlodipine survival evaluation 2)

Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction

Effect of oral milrinone on mortality in severe chronic heart failure

Effects of low-dose oral enoximone administration on mortality, morbidity, and exercise capacity in patients with advanced heart failure: the randomized, double-blind, placebo-controlled, parallel group ESSENTIAL trials

Low-dose oral enoximone enhances the ability to wean patients with ultra-advanced heart failure from intravenous inotropic support: results of the oral enoximone in intravenous inotrope-dependent subjects trial

Oral levosimendan in patients with severe chronic heart failure --the PERSIST study

Long-Term Effects of Flosequinan on the Morbidity and Mortality of Patients With Severe Chronic Heart Failure: Primary Results of the PROFILE Trial After 24 Years

Randomised study of effect of ibopamine on survival in patients with advanced severe heart failure. Second Prospective Randomised Study of Ibopamine on Mortality and Efficacy (PRIME II) Investigators

Xamoterol in severe heart failure. The Xamoterol in Severe Heart Failure Study Group

Long-term oral administration of amrinone for congestive heart failure: lack of efficacy in a multicenter controlled trial

Severe liver dysfunction

Acute coronary syndrome within 4 weeks as defined by electrocardiographic (ECG) changes and biomarkers of myocardial necrosis (e.g. troponin) in an appropriate clinical setting

Planned or recent (≤ 4 weeks) PCI, coronary artery bypass grafting

Primary hypertrophic or infiltrative cardiomyopathy, acute myocarditis, constrictive pericarditis or tamponade

ACS = acute coronary syndrome

CABG = coronary artery bypass graft

ECG = electrocardiogram; eGFR = estimated glomerular filtration rate

GDMT = guideline directed medical therapy

HFrEF = heart failure with a reduced Ejection Fraction; IV = intravenous

LVAD = left ventricular assist device

LVEF = left ventricular ejection fraction; NT-proBNP = N-terminal pro-B-type natriuretic peptide

PCI = percutaneous coronary intervention

RER = respiratory exchange ratio

SBP = systolic blood pressure; VO 2 = oxygen consumption; 6-MWT = 6-minute walk test

Amrinone 34% (p = 0.01) AE = adverse event; CV = cardiovascular; HF = heart failure; LVEF = left ventricular ejection fraction; MLWHQ = Minnesota Living with Heart Failure Questionnaire; NICM = nonischemic cardiomyopathy; NYHA = New York Heart Association; sec = seconds; 6-MWD = 6-minute walk distance. *Enrolled patients had NYHA II-IV heart failure with worsening HF defined as recent HF hospitalization or need for IV diuretic therapy.